Phase III study of chlorambucil versus fludarabine as initial therapy for Waldenström's macroglobulinemia and related disorders

Clinical Lymphoma

Volumn 5, Issue 4, 2005, Pages 294-297

  Johnson, Stephen A ^a   Owen, Roger G ^b   Oscier, David G ^c   Leblond, Veronique ^d   Levy, Vincent ^e   Jaeger, Ulrich ^f   Seymour, John F ^g  

^a TAUNTON AND SOMERSET HOSPITAL   (United Kingdom)

^b LEEDS GENERAL INFIRMARY   (United Kingdom)

^c ROYAL BOURNEMOUTH HOSPITAL   (United Kingdom)

^d PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^e SAINT LOUIS HOSPITAL   (France)

^f Abteilung Angiologie   (Austria)

^g PETER MACCALLUM CANCER CENTRE   (Australia)

Author keywords

CD20; Lymphoplasmacytic lymphoma; Paraprotein; Purine analogues; Rituximab; Splenic lymphoma; Villous lymphocytes

Indexed keywords

CHLORAMBUCIL; FLUDARABINE;

ARTICLE; CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; FOLLOW UP; HUMAN; HYPERVISCOSITY SYNDROME; IMMUNOPHENOTYPING; INTERNET; LYMPHOCYTOMA; LYMPHOMA; NEUTROPENIA; OPEN STUDY; PHASE 3 CLINICAL TRIAL; PLASMAPHERESIS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RELAPSE; SPLEEN LYMPHOMA; SPLENECTOMY; SURVIVAL RATE; THROMBOCYTOPENIA; TREATMENT INDICATION; TREATMENT OUTCOME; WALDENSTROEM MACROGLOBULINEMIA;

EID: 18144407281     PISSN: 15269655     EISSN: None     Source Type: Journal    
DOI: 10.3816/CLM.2005.n.020     Document Type: Article

References (29)

1. Harris NL, Jaffe ES, Stein H, et al. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood 1994;84:1361-1392.
2. Harris NL, Jaffe ES, Diebold J, et al. World Health Organisation Classification of Neoplastic Diseases of the Hematopoietic and Lymphoid tissues: report of the Clinical Advisory Committee meeting - Airlie House, Virginia, November 1997. J Clin Oncol 1999; 17:3835-3849.
3. Owen RG, Treon SP, Al-Katib A, et al. Clinicopathological definition of Waldenstrom's macroglobulinemia: Consensus Panel Recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia. Semin Oncol 2003; 30:110-115.
4. Kyle RA, Treon SP, Alexanian R, et al. Prognostic markers and criteria to initiate therapy in Waldenstrom's Macroglobulinemia: Consensus panel recommendations from the second international workshop on Waldenstrom's Macroglobulinemia. Semin Oncol 2003; 30:116-120.
5. Weber D, Treon SP, Emmanoulides C, et al. Uniform response criteria in Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia. Semin Oncol 2003; 30:127-131.
6. Dimopoulous MA, Alexanian R. Waldenstrom's macroglobulinemia. Blood 1994; 83:1452-1459
7. McCallister BD, Bayrd ED, Harrison EG, et al. Primary macroglobulinemia: review with a report on thirty-one cases and notes on the value of continuous chlorambucil therapy. Am J Med 1967; 43:394-434.
8. MacKenzie MR, Fudenberg HH. Macroglobulinemia: an analysis for forty patients. Blood 1972; 39:874-889.
9. Facon T, Brouillard M, Duhamel A, et al. Prognostic factors in Waldenstrom's macroglobulinemia: a report of 167 cases. J Clin Oncol 1993; 11:1553-1558.
10. Kyle RA, Griepp PR, Gertz MA, et al. Waldenstrom's macroglobulinemia: a prospective study-comparing daily versus intermittent oral chlorambucil. Blood 1998; 92(suppl):2796a.
11. Petrucci MT, Avvisati G, Tribalto M, et al. Waldenstrom's macroglobulinaemia: results of a combined oral treatment in 34 newly diagnosed patients. J Int Med 1989; 226:443-447.
12. Case DC, Ervin TJ, Boyd MA, et al. Waldenstrom's macroglobulinaemia: long term results with the M2 protocol. Cancer Invest 1991; 9:1-7.
13. Kantarjian HM, Alexanian R, Koller CA, et al. Fludarabine therapy in macroglobulinemic lymphoma. Blood 1990; 75:1928-1931.
14. Dimopoulos MA, O'Brien S, Kantarjian H, et al. Fludarabine therapy in Waldenstrom's macroglobulinaemia. Am J Med 1993; 95:49-52.
15. Zinzani PL, Gherlinzoni F, Bendandi M, et al. Fludarabine treatment in resistant Waldenstrom's macroglobulinaemia. Eur J Haematol 1995; 54:120-123.
16. Leblond V, Ben-Othman T, Deconinck E, et al. Activity of fludarabine in previously treated Waldenstrom's macroglobulinemia: a report of 71 cases. J Clin Oncol 1998; 16:2060-2064.
17. Dimopoulos MA, Weber D, Delasalle KB, et al. Treatment of Waldenstrom's macroglobulinaemia resistant to standard therapy with 2-chlorodeoxyadenosine: identification of prognostic factors. Ann Oncol 1995; 6:49-52.
18. Betticher DC, Hsu Schmitz SF, Ratschiller D, et al. Cladribine (2-CDA) given as subcutaneous bolus injections is active in pretreated Waldenstrom's macroglobulinaemia. Br J Haematol 1995; 99:358-363.
19. Liu ES, Burian C, Miller WE, et al. Bolus administration of cladribine in the treatment of Waldenstrom's macroglobulinaemia. Br J Haematol 1998; 103:690-695.
20. Leblond V, Levy V, Maloisel F, et al. French Cooperative Group on Chronic Lymphocytic Leukemia and Macroglobulinemia Multicenter Randomized comparative trial of fludarabine and the combination of cyclophosphamide-doxorubicin-prednisone in 92 patients with Waldenstrom macroglobulinemia in first relapse or with primary refractory disease. Blood 2001, 98:2640-2644.
21. Dimopoulos MA, Kantarjian H, Weber D, et al. Primary therapy of Waldenstrom's macroglobulinemia with 2-chlorodeoxyadenosine. J Clin Oncol 1994; 12:2694-2698.
22. Fridrik MA, Jager G, Baldinger C, et al. First-line treatment of Waldenstrom's disease with cladribine. Ann Hematol 1997; 74:7-10.
23. Foran JM, Rohatiner AZS, Coiffier B, et al. Multicenter phase II study of fludarabine phosphate for patients with newly diagnosed lymphoplasmacytoid lymphoma, Waldenstrom's macroglobulinemia and mantle-cell lymphoma. J Clin Oncol 1999; 17:546-553
24. Byrd JC, White CA, Link B, et al. Rituximab therapy in Waldenström's macroglobulinemia: preliminary evidence of clinical activity. Ann Oncol 1999; 10:525-1527.
25. Gertz MA, Anagnostopoulos A, Anderson K, et al. Treatment recommendations in Waldenstrom's Macroglobulinemia: Consensus Panel Recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia. Semin Oncol 2003; 30:121-126.
26. Mulligan SP, Matutes E, Dearden C, et al. Splenic lymphoma with villous lymphocyes: natural history and response to therapy in 50 cases. Br J Haematol 1991; 78:206-209.
27. Bolam S, Orchad J, Oscier D. Fludarabine is effective in the treatment of splenic lymphoma with villous lymphocytes. Br J Haematol 1995; 99:158-161.
28. Virchis A, Mehta A. Splenic lymphoma with villous lymphocytes (SLVL) responding to 2-chlorodeoxyadenosine (2-CdA). Br J Haematol 1998; 100:609.
29. Papamichael D, Norton AJ, Foran JM, et al. Immunocytoma: a retrospective analysis from St. Bartholomew's Hospital - 1972 to 1996. J Clin Oncol 1999; 17:2847-2853.